Literature DB >> 10093016

[Significance of silent myocardial ischemia for identification and optimal therapy of patients with latent coronary heart disease. Is there a marker for prognostic indication for PTCA?].

D Hering1, H P Schultheiss, D Horstkotte.   

Abstract

Although percutaneous transluminal coronary angioplasty (PTCA) improves the symptomatic status and exercise capacity of patients with coronary artery disease and stale or unstable angina pectoris, a beneficial effect on long-term prognosis has not been convincingly demonstrated so far. In totally asymptomatic patients with coronary artery disease, however, decision to undertake PTCA is greatly influenced by prognostic considerations. Usually, detection of silent myocardial ischemia in non-invasive examinations (exercise stress testing, ambulatory electrocardiographic monitoring) precedes the angiographic diagnosis of coronary artery disease in these patients.

Entities:  

Mesh:

Year:  1999        PMID: 10093016     DOI: 10.1007/bf03043821

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  67 in total

1.  [Transluminal coronary angioplasty. Arguments against a prognostic indication].

Authors:  W Rutsch
Journal:  Z Kardiol       Date:  1998

2.  Relation between clinical, angiographic and ischemic findings at baseline and ischemia-related adverse outcomes at 1 year in the Asymptomatic Cardiac Ischemia Pilot study. ACIP Study Group.

Authors:  C J Pepine; B Sharaf; T C Andrews; S Forman; N Geller; G Knatterud; J Mahmarian; P Ouyang; W J Rogers; G Sopko; R Steingart; P H Stone; C R Conti
Journal:  J Am Coll Cardiol       Date:  1997-06       Impact factor: 24.094

3.  Percutaneous transluminal coronary angioplasty in patients with silent myocardial ischemia during exercise testing.

Authors:  L Finci; B Meier; P Roy; A Righetti; W Rutishauser
Journal:  Herz       Date:  1987-12       Impact factor: 1.443

4.  Risk of developing an acute myocardial infarction or sudden coronary death in patients with exercise-induced silent myocardial ischemia. A report from the Coronary Artery Surgery Study (CASS) registry.

Authors:  D A Weiner; T J Ryan; C H McCabe; G Ng; B R Chaitman; L T Sheffield; F E Tristani; L D Fisher
Journal:  Am J Cardiol       Date:  1988-12-01       Impact factor: 2.778

5.  Cardiovascular mortality and morbidity in type-2 diabetes mellitus.

Authors:  G Schernthaner
Journal:  Diabetes Res Clin Pract       Date:  1996-07       Impact factor: 5.602

6.  Asymptomatic Cardiac Ischemia Pilot (ACIP) study: impact of anti-ischemia therapy on 12-week rest electrocardiogram and exercise test outcomes. The ACIP Investigators.

Authors:  B R Chaitman; P H Stone; G L Knatterud; S A Forman; G Sopko; M G Bourassa; C Pratt; W J Rogers; C J Pepine; C R Conti
Journal:  J Am Coll Cardiol       Date:  1995-09       Impact factor: 24.094

Review 7.  Treatment strategies for daily life silent myocardial ischemia: a correlation with potential pathogenic mechanisms.

Authors:  B D Bertolet; J A Hill; C J Pepine
Journal:  Prog Cardiovasc Dis       Date:  1992 Sep-Oct       Impact factor: 8.194

Review 8.  [Ischemia--reliable results of therapy, operation and angioplasty--in coronary disease].

Authors:  U Zeymer; K L Neuhaus
Journal:  Z Kardiol       Date:  1993

9.  Prognostic significance of transient myocardial ischemia on ambulatory monitoring after acute myocardial infarction.

Authors:  P Currie; D Ashby; S Saltissi
Journal:  Am J Cardiol       Date:  1993-04-01       Impact factor: 2.778

10.  Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST)

Authors:  C J Pepine; P F Cohn; P C Deedwania; R S Gibson; E Handberg; J A Hill; E Miller; R G Marks; U Thadani
Journal:  Circulation       Date:  1994-08       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.